Skip to main content
letter
. 2015 Jun 4;17(8):800–804. doi: 10.1111/dom.12481

Figure 1.

DOM-12481-FIG-0001-c

(A) Twenty‐four‐hour plasma glucose levels, as measured by continuous glucose monitoring after 7 days of once‐daily administration of 2.5 mg luseogliflozin or placebo. Values are means ± standard deviation (s.d.). Glucose: 1 mg/dl = 0.0556 mmol/l. (B) Twenty‐four‐hour serum insulin levels after 7 days of once‐daily administration of 2.5 mg luseogliflozin or placebo. Values are means ± s.d. *p < 0.05 for luseogliflozin versus placebo. Insulin: 1 µU/ml = 6.945 pmol/l. (C) Twenty‐four‐hour plasma glucagon levels after 7 days of once‐daily administration of 2.5 mg luseogliflozin or placebo. Values are means ± s.d. *p < 0.05 for luseogliflozin versus placebo. Glucagon: 1 pg/ml = 1 ng/l. (D) Cumulative urinary glucose excretion after 7 days of once‐daily administration of 2.5 mg luseogliflozin or placebo. Values are means ± s.d. *p < 0.05 for luseogliflozin versus placebo.